The results showed a 27% decrease in memory and thinking deterioration in early stage Alzheimer’s; an encouraging solution to help maintain mental function and cognitive ability.
Lecanemab was officially approved by the FDA as an early Alzheimer's drug treatment in January 2023, following last year’s clinical trial success. The results showed a 27% decrease in memory and thinking deterioration in early stage Alzheimer’s; an encouraging solution to help maintain mental function and cognitive ability.